Sanofi's New Cancer Drug Could Help Deliver a Big Payday [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Why you should consider buying Sanofi Sanofi's rilzabrutinib performed well in its phase 3 clinical trial, meaning the company can now apply for approval. The drug is a type of BTK inhibitor that combats disorders found in B lymphocytes, also known as B cells. BTK inhibitors have shown effectiveness as a treatment for such diseases as non-Hodgkin lymphomas. The excitement over its clinical trial success stems from its efficacy compared to the competition. Rilzabrutinib works at a smaller dosage and has fewer unwanted side effects. Those traits immediately make the drug promising in the marketplace. In addition, rilzabrutinib's ability to work effectively in low dosages has developers confident that the drug could be used against other diseases beyond the B cell type. That's why Sanofi sees the potential for big future sales. In late December, Sanofi said that by 2030, it expected $11 billion in added annual sales from 12 drugs -- including five that are already launched and sev
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game [Yahoo! Finance]Yahoo! Finance
- Type 1 Diabetes Market Size to Worth USD 24.36 Bn By 2031 [Yahoo! Finance]Yahoo! Finance
- Takeda's dengue vaccine obtains WHO prequalification [Yahoo! Finance]Yahoo! Finance
- Exploring Groupe LDLC Société Anonyme And Two More Top Dividend Stocks On Euronext Paris [Yahoo! Finance]Yahoo! Finance
- WHO approves second vaccine against the mosquito-borne disease dengue as outbreaks intensify [FOX News]FOX News
SNY
Sec Filings
- 5/2/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/4/24 - Form F-3ASR
- SNY's page on the SEC website